Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PTC Therapeutics is a rare disease-focused biopharmaceutical company commercializing treatments for Duchenne muscular dystrophy (Translarna in ex-US markets, generating ~$500M annually) and aromatic L-amino acid decarboxylase (AADC) deficiency (Upstaza gene therapy). The company operates in high-margin orphan drug markets with limited competition but faces significant R&D burn, patent expiration risks on Translarna (2025-2027 in key markets), and binary clinical trial outcomes that drive stock volatility.
PTC generates revenue through ultra-orphan drug pricing ($300K-$3M+ per patient annually or one-time for gene therapy) with minimal direct competition in approved indications. Translarna benefits from conditional EU approval despite mixed Phase 3 data, creating regulatory risk but current market exclusivity. The company leverages accelerated approval pathways, compassionate use programs, and managed access arrangements to generate revenue while conducting confirmatory trials. Gross margins exceed 90% due to specialty pharmaceutical economics, but the company remains unprofitable due to $300M+ annual R&D spend on pipeline programs including PTC518 (Huntington's), PTC-AADC (next-gen gene therapy), and sepiapterin reductase deficiency programs.
Translarna regulatory decisions - EMA annual renewal of conditional approval (typically Q3-Q4), potential FDA approval attempts, and patent expiration timeline in EU (2025-2027 depending on jurisdiction)
Clinical trial readouts for pipeline assets - PTC518 Phase 2 data in Huntington's disease, PTC-AADC gene therapy updates, sepiapterin reductase deficiency program milestones
Upstaza commercial uptake - quarterly patient starts, reimbursement approvals in new markets (US filing potential), and manufacturing capacity expansion
Business development activity - licensing deals, asset acquisitions to diversify beyond Duchenne franchise, or potential sale of non-core assets
Quarterly revenue performance vs consensus - particularly Translarna geographic mix and Upstaza patient additions
Translarna patent cliff (2025-2027 in EU markets) with no clear replacement franchise - represents 60%+ of current revenue with limited barriers to generic entry post-expiration despite orphan exclusivity
Gene therapy manufacturing complexity and scalability - Upstaza requires specialized AAV vector production with limited CDMO capacity, constraining patient throughput to 50-100 annually vs 1,000+ addressable AADC population
Regulatory risk on conditional approvals - EMA could withdraw Translarna authorization if confirmatory trials fail to demonstrate clinical benefit, eliminating majority of revenue base
Rare disease market size constraints - even with 100% market share, individual indications generate $100-500M peak sales, requiring continuous pipeline replenishment
Sarepta Therapeutics' gene therapy programs (SRP-9001) for Duchenne could render Translarna obsolete if approved, capturing nonsense mutation patients with superior efficacy
Emerging exon-skipping therapies and CRISPR-based approaches in Duchenne create long-term obsolescence risk for small molecule and first-generation gene therapies
Competitive gene therapy programs in AADC deficiency from academic centers and emerging biotechs could fragment Upstaza market share
Large pharma entry into rare disease space (Roche, Novartis, BMS) through M&A creates well-capitalized competitors with superior commercial infrastructure
Negative shareholder equity of -$1.5B and accumulated deficit create financial fragility - company cannot sustain current burn rate beyond 2027 without additional financing or achieving profitability
Convertible debt maturities in 2027-2028 ($500M+) will require refinancing or conversion, potentially diluting existing shareholders by 20-30% if stock price remains below conversion price
Operating cash flow negative $100M annually with free cash flow negative $200M creates dependency on capital markets access - any disruption to biotech financing environment threatens viability
Limited tangible assets ($200M vs $5.5B market cap) provide minimal liquidation value, making equity valuation entirely dependent on pipeline execution
low - Rare disease treatments exhibit minimal GDP sensitivity as patient populations are defined by genetic mutations rather than economic conditions. Payer willingness to reimburse ultra-orphan drugs remains stable across cycles due to lack of therapeutic alternatives and societal pressure to fund life-saving treatments. However, government healthcare budget constraints during recessions can delay reimbursement approvals in emerging markets (Latin America, Eastern Europe) where Translarna expansion is occurring.
Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress NPV of long-duration pipeline assets, particularly gene therapies with 10-15 year development timelines, reducing valuation multiples for pre-profitable biotech from 8-12x forward sales to 3-5x. (2) Increased financing costs impact the company's ability to fund $300M+ annual cash burn through debt markets, though current $600M+ cash position and 2.3x current ratio provide near-term cushion. The company's negative equity position (-$16.0 D/E ratio) reflects accumulated losses rather than leverage risk.
Moderate exposure to credit conditions. The company requires access to capital markets to fund operations until profitability (estimated 2026-2027). Tightening credit spreads increase convertible debt costs and reduce financing flexibility for M&A. However, rare disease biotech maintains investor appeal during most credit environments due to binary value creation from clinical catalysts. High-yield spreads above 500bps historically correlate with biotech sector underperformance and reduced IPO/follow-on activity that limits strategic options.
growth/speculative - Attracts biotech-focused growth investors and event-driven hedge funds playing clinical catalysts and regulatory binary outcomes. The negative earnings, high R&D spend, and pipeline-dependent valuation appeal to investors with 3-5 year time horizons willing to underwrite 50%+ volatility for potential multi-bagger returns from successful drug approvals. Not suitable for value or income investors given negative equity, no dividends, and lack of current profitability. Recent 39% one-year return reflects momentum following positive clinical updates, but -10% three-month return shows sensitivity to sector rotation and risk-off periods.
high - Biotech stocks with concentrated revenue bases and binary clinical catalysts typically exhibit 50-80% annualized volatility and betas of 1.3-1.8x. Single-day moves of 20-40% occur around FDA decisions, clinical data releases, and partnership announcements. The stock trades on low institutional ownership outside specialized healthcare funds, creating liquidity constraints and amplified price swings. Options market typically prices 60-80% implied volatility around known catalyst dates.
